Molecular pathways and molecular imaging in breast cancer: An update

Cervino, Anna Rita; Burei, Marta; Mansi, Luigi; Evangelista, Laura

doi:10.1016/j.nucmedbio.2013.03.002

Cited by 13 publications

(13 citation statements)

References 113 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, 18 F-fluoroestradiol is used to image the oestrogen receptor, which is highly overexpressed in B70-80% of breast tumour tissues, whereas radiolabelled trastuzumab is used to target human epidermal growth factor receptor 2, which is overexpressed in 25-30% of breast cancer patients with oestrogen receptor-negative disease [1]. Many other radiotracers have been designed to image amino-acid transporters and protein synthesis (radiolabelled methionine), cell proliferation ( 18 F-fluorothymidine), apoptosis (radiolabelled Annexin V), increased mitogenic activity (radiolabelled bombesin peptides), angiogenesis (radiolabelled RGD peptides) and other features of breast cells.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Kit preparation and biokinetics in women of 99mTc-EDDA/HYNIC-E-[c(RGDfK)]2 for breast cancer imaging

Ortiz-Arzate

Santos-Cuevas

Ocampo‐García

et al. 2014

Nuclear Medicine Communications

View full text Add to dashboard Cite

All absorbed doses were comparable to those known from most of the (99m)Tc studies. (99m)Tc-EDDA/HYNIC-E-[c(RGDfK)]2 obtained from kit formulations showed high tumour uptake in patients with malignant lesions, making it a promising imaging radiopharmaceutical for targeting site-specific breast cancer. The results obtained in this study warrant further clinical studies to determine the specificity and sensitivity of (99m)Tc-EDDA/HYNIC-E-[c(RGDfK)]2.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Breast cancer is one of the most frequently occurring cancers in women and the most common cause of cancer mortality among them [1]. The high mortality rate associated with breast cancer is directly related to its ability to readily metastasize [2].…”

Section: Introductionmentioning

confidence: 99%

Kit preparation and biokinetics in women of 99mTc-EDDA/HYNIC-E-[c(RGDfK)]2 for breast cancer imaging

Ortiz-Arzate

Santos-Cuevas

Ocampo‐García

et al. 2014

Nuclear Medicine Communications

View full text Add to dashboard Cite

show abstract

“…The estrogen receptor (ER) is a nuclear receptor expressed in approximately 75 % of breast cancer cases . Therefore, ER is a well‐established biomarker for prognosis and guiding treatment and is an important target for new imaging and therapeutic tools aiming to improve BC management . In fact, the most pressing need in cancer management is to design effective and personalized treatments that minimize damage to the normal cells.…”

Section: Methodsmentioning

confidence: 99%

A Multifunctional Radiotheranostic Agent for Dual Targeting of Breast Cancer Cells

et al. 2017

View full text Add to dashboard Cite

A straightforward synthetic route for a new multifunctional 1,4,7,10‐tetraazacyclododecane‐1,4,7,10‐tetraacetic acid (DOTA) derivative is described. To demonstrate the versatility of this pro‐chelator for the preparation of radiolabeled hybrid compounds containing two different biological targeting moieties, an antitumor agent (e.g., a DNA‐intercalating agent) and an estrogen receptor (ER) ligand (e.g., LXXLL‐based peptide) were regiospecifically conjugated to the DOTA derivative. The bifunctional probe was radiolabeled with the auger electron emitter indium‐111, and the resulting radioconjugate was demonstrated to induce DNA damage in vitro, which, along with the nuclear internalization exhibited in breast cancer cells, might enhance its therapeutic activity. This favorable in vitro performance suggests that these hybrid compounds could be attractive probes for theranostic applications.

show abstract

“…Several agents have been proposed for PET imaging of DNA synthesis, including 18 F-fluorothymidine (FLT), 76 Br-bromodeoyxuridine, 11 C-thymidine, and derivatives of mdeoxy-18 F-fluoroarabinofuranosyl such as 18 F-FAU, 18 F-FMAU, 18 F-FBAU, and 18 F-FIAU. Among all these radiotracers mainly tested in clinical studies, FLT has emerged as the most promising PET tracer in recent studies (Cervino et al, 2013). Crippa et al (2015) suggest the potential utility of FLT PET scans for early monitoring of response to neoadjuvant chemotherapy and to formulate a therapeutic strategy (Crippa et al, 2015).…”

Section: Targeting Of Her2mentioning

confidence: 99%

Positron emission tomography in breast cancer: 18F- FDG and other radiopharmaceuticals

Iakovou

Giannoula

Gkantaifi

et al. 2018

European J Hybrid Imaging

View full text Add to dashboard Cite

Background: Breast cancer heterogeneity reflects the complex biology of this disease. Breast cancer subtypes, as identified either by immunohistochemistry (IHC) or by gene expression analysis, present different molecular characteristics and prognosis. In this context, molecular imaging techniques providing functional information, contribute in evaluating response to treatment and long-term prognosis among different subtypes. Nuclear imaging diagnosis modalities play an important role for conducting research on cancer biology and developing new treatment approaches. Positron Emission Tomography (PET) is a radionuclide based imaging method that has the potential to locate the tumor, define its staging, and monitor its response to treatment.Results: In the current study, we will review the utility of the most widely used molecular imaging technique, 18 F-fluorodeoxyglucose ( 18 F-FDG) PET, in order to determine the relationship between standardized uptake values (SUVs) and immunohistopathological factors, as well as to clarify whether PET is able to predict breast cancer phenotypes. Moreover, we will discuss the rising development of new radiopharmaceuticals in PET imaging, such as 18 F-fluoro-17-estradiol (FES), 18 F-fluoro-l-thymidine (FLT), 18 F-fluoromisonidazole (FISO), and 89 Zr-immuno-PET, which give more information about tumor characteristics. Conclusions: In order to improve clinical decision making, enabling hereafter more successful individualized therapies, it is imperative to combine PET radiopharmaceuticals and imaging techniques of critical biologic and pathologic phenomena, including ER, PR and HER2 expression, angiogenesis, hypoxia, apoptosis and metabolic changes in the microenviroment of breast tumors. BackgroundBreast cancer is the most frequently diagnosed noncutaneous malignancy in women worldwide, accounting for approximately 30% of all new cancer diagnoses and about 14% of all cancer deaths in women. About 63,410 new cases of female breast carcinoma in situ and 252,710 new cases of invasive breast cancer will be diagnosed in 2017 among United States (US) women. It is estimated that one in eight women will develop breast cancer during their life, while it is the second most common cause of cancer

show abstract

Molecular pathways and molecular imaging in breast cancer: An update

Cited by 13 publications

References 113 publications

Kit preparation and biokinetics in women of 99mTc-EDDA/HYNIC-E-[c(RGDfK)]2 for breast cancer imaging

Kit preparation and biokinetics in women of 99mTc-EDDA/HYNIC-E-[c(RGDfK)]2 for breast cancer imaging

A Multifunctional Radiotheranostic Agent for Dual Targeting of Breast Cancer Cells

Positron emission tomography in breast cancer: 18F- FDG and other radiopharmaceuticals

Contact Info

Product

Resources

About